Trial reportEuropean radiology2018
Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate.
Trial report in European radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- Image Quality and Diagnostic Performance of Accelerated T2-weighted Imaging of Prostate with Deep Learning Reconstruction: A Comparative Study.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Article
- The evolving PI-RADS paradigm.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Review
- Prostate MRI in the United Kingdom: a survey of current practice by the British Society of Urogenital Radiology.The British journal of radiology · 2026Article
- Evaluating spatial resolution in prostate MR images: the utility of the ladder method.Magma (New York, N.Y.) · 2025Article
- Prevalence and Significance of Incidental Findings in Multiparametric Magnetic Resonance Imaging of the Prostate.Tomography (Ann Arbor, Mich.) · 2025Article
- Risk factors for motion artifacts in fast spin-echo T2-weighted imaging of the prostate magnetic resonance imaging: a retrospective study.Radiological physics and technology · 2025Article
- The impact of modifiable factors on image quality of prostate magnetic resonance imaging and PI-RADS scores.Quantitative imaging in medicine and surgery · 2025Article
- PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI.European radiology · 2024Article
- Antispasmodic Agents in Magnetic Resonance Imaging of the Urinary Bladder-A Narrative Review.Cancers · 2024Review
- The effect of butylscopolamine on [EJNMMI research · 2023Article
- Assessment of T2-weighted Image Quality at Prostate MRI in Patients with and Those without Intramuscular Injection of Glucagon.Radiology. Imaging cancer · 2023Article
- Prostate MRI and image Quality: It is time to take stock.European journal of radiology · 2023Review
- State-of-the-art Prostate Imaging.Sisli Etfal Hastanesi tip bulteni · 2023Review
- [Prostate Imaging Reporting and Data System (PI-RADS) v 2.1: Overview and Critical Points].Journal of the Korean Society of Radiology · 2023Review
- Article
- [Multiparametric MRI of the prostate].Der Urologe. Ausg. A · 2022Article
- Deep learning-based artificial intelligence applications in prostate MRI: brief summary.The British journal of radiology · 2022Review
- Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score.The British journal of radiology · 2022Review
- Do antispasmodics or rectal enemas improve image quality on multiparametric prostate MRI? An 'Evidence-Based Practice' review of the literature.Abdominal radiology (New York) · 2021Review
- Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists.Insights into imaging · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo prospectively evaluate the effect of hyoscine butylbromide (HBB) on visualisation of anatomical details and motion-related artefacts in mp-MRI of the prostate at 3.0 Tesla.
methodsOne hundred and three consecutive patients (65 ± 10 years) were included in this trial, powered to demonstrate an improvement of image quality after HBB administration, assessed on a 5-point scale by two blinded readers. All patients received high-spatial resolution axial T2-weighted TSE sequences at 3.0 T without spasmolytic agent, repeated after application of 40 mg HBB and followed by routine mp-MRI. Secondary endpoints were (1) susceptibility to side effects, (2) dependence of spasmolytic effect on patients´ weight, and (3) prostate volume.
resultsIn 68% of patients, HBB significantly improved the anatomic score (mean 3.4 ± 0.9 before and 4.4 ± 0.7 after HBB for both readers, p = <0.001). In 67%, HBB significantly enhanced the artefact score (mean 3.2 ± 1 before and 4.2 ± 0.8 after HBB for reader 1, p = <0.001; 3.2 ± 1 and 4.1 ± 0.8 for reader 2, p = <0.001). Subgroup analysis revealed no statistically significant difference between patients with different bodyweight or prostate volume. Inter-reader agreement was excellent (k = 0.95-0.98).
conclusionsHyoscine butylbromide significantly improves image quality and reduces motion-related artefacts in mp-MRI of the prostate independent of bodyweight or prostate volume. No side effects were reported. KEY POINTS: • Hyoscine butylbromide (HBB) improved image quality in over 2/3 of patients. • Severe artefacts were reduced after HBB in more than 20%. • The number of non-diagnostic MRI was reduced to <1% after HBB. • HBB effect was independent of bodyweight and prostate volume. • No side effects of HBB were reported in this study population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.